- Positive feedback from pre-IND meeting with FDA confirms Hikma’s continued development of AT307 under the 505(b)(2) regulatory pathway
- Abbreviated 505(b)(2) submission offers an efficient and streamlined development pathway with reduced risk
In January 2023, Arecor transferred all rights and responsibility for future development and commercialisation of AT307 to Hikma as part of an earlier co-development and license agreement in which Arecor used its proprietary drug formulation technology platform, Arestat™, to develop a novel RTU formulation of an existing therapeutic product.
Based on positive feedback from a pre-IND meeting held with the FDA, Hikma has communicated to Arecor its intention to continue development of AT307 in the US using the FDA’s 505(b)(2) regulatory pathway. This pathway provides companies with an abbreviated regulatory review process when evidence of safety and clinical efficacy generated for an originator product is deemed suitable to be relied upon in new marketing applications.
Sarah Howell, Chief Executive Officer at Arecor, said: “We are very pleased with this confirmatory news that Hikma is able to pursue an abbreviated 505(b)(2) approval pathway for AT307, providing an opportunity to progress the development and regulatory review process and bring this medicine to patients more rapidly than through a traditional new drug approval route. This also further validates a fundamental assumption within our business that the abbreviated 505(b)(2) pathway can be utilised across our specialty hospital portfolio where we are developing enhanced, ready-to-use and ready-to-administer formulations of existing therapeutic products.”
Bill Larkins, President of Injectables at Hikma, said: “The FDA’s feedback supports our intention to pursue a 505(b)(2) pathway to market for AT307, so we can bring this important new ready-to-use treatment option to patients. It also further demonstrates the strength of the Hikma and Arecor strategic partnership where we are leveraging our respective strengths to bring this important treatment option to patients and healthcare providers and further position our business for continued long-term growth. We look forward to advancing AT307 through further development and to continuing our highly productive strategic collaboration with Arecor.”
Under the terms of Arecor’s 2020 co-development and license agreement with Hikma, the Group is eligible to receive development milestone payments in addition to future recurring revenue from royalty payments upon commercialisation.
